The stock of Calithera Biosciences Inc (NASDAQ:CALA) is a huge mover today! About 178,725 shares traded hands. Calithera Biosciences Inc (NASDAQ:CALA) has declined 47.45% since March 8, 2016 and is downtrending. It has underperformed by 56.77% the S&P500.
The move comes after 7 months negative chart setup for the $61.37 million company. It was reported on Oct, 11 by Barchart.com. We have $2.74 PT which if reached, will make NASDAQ:CALA worth $6.75M less.
Analysts await Calithera Biosciences Inc (NASDAQ:CALA) to report earnings on November, 14. They expect $-0.47 EPS, up 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual EPS reported by Calithera Biosciences Inc for the previous quarter, Wall Street now forecasts -14.55% EPS growth.
Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage
Out of 3 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Calithera Biosciences has been the topic of 3 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Citigroup initiated Calithera Biosciences Inc (NASDAQ:CALA) on Friday, July 24 with “Buy” rating. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report.
According to Zacks Investment Research, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 0.47 in 2016 Q2. Its down 0.57, from 1.04 in 2016Q1. The ratio turned negative, as 16 funds sold all Calithera Biosciences Inc shares owned while 18 reduced positions. 9 funds bought stakes while 7 increased positions. They now own 7.04 million shares or 18.29% less from 8.61 million shares in 2016Q1.
Credit Suisse Ag holds 53,183 shares or 0% of its portfolio. Aqr Cap Mngmt Lc has 24,395 shares for 0% of their US portfolio. Moreover, Wells Fargo & Mn has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 53,405 shares. Paloma Prns Management Com last reported 0% of its portfolio in the stock. Art Ltd has 0% invested in the company for 14,451 shares. First Eagle Inv Limited Liability Company has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Connor Clark & Lunn Invest Management Ltd reported 10,500 shares or 0% of all its holdings. Moreover, D E Shaw has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 37,249 shares. Moreover, Franklin Street Nc has 0.06% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 84,300 shares. Bvf Il owns 121,400 shares or 0.1% of their US portfolio. Geode Limited Liability has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Howland Cap Mgmt Limited Company holds 12,000 shares or 0% of its portfolio. Goldman Sachs Grp has 0% invested in the company for 24,458 shares. Gsa Capital Prtn Ltd Liability Partnership holds 0.01% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA) for 43,800 shares. Lmr Prns Llp holds 14,573 shares or 0.01% of its portfolio.
More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Quotes.Wsj.com which released: “News Calithera Biosciences Inc.CALA” on February 17, 2011, also Prnewswire.com with their article: “ProTrials Research, Inc. Selected by Calithera Biosciences, Inc. for Early …” published on July 25, 2016, Globenewswire.com published: “Calithera Biosciences to Present at the Leerink Partners Roundtable Series …” on September 22, 2016. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: Equitiesfocus.com and their article: “Calithera Biosciences, Inc. (NASDAQ:CALA) Basic Consolidated EPS At $-1.809” published on October 09, 2016 as well as Globenewswire.com‘s news article titled: “Calithera Biosciences Selects Immuno-Oncology Clinical Candidate CB-1158, an …” with publication date: June 23, 2015.
CALA Company Profile
Calithera Biosciences, Inc., incorporated on March 9, 2010, is a clinical-stage pharmaceutical company. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Firm is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company’s lead product candidate, CB-839, is a critical enzyme in tumor cells. The Company’s other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. The Company’s lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.